Audrey Sabbagh

Audrey Sabbagh

Auto-generated profile, based on publicly available information

Audrey Sabbagh

Unit Mother and Child face to tropical infections, UMR IRD 216, University Paris Descartes, Paris, France

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2010 in The FASEB Journal
Verified
Journal Article
Closed access
EPEric Pasmant
Eric Pasmant
ASAudrey Sabbagh
Audrey Sabbagh
MVMichel Vidaud
Michel Vidaud
IBIvan Bieche
Ivan Bieche

10 May 2010 in Human Mutation
Verified
Journal Article
Open access
PDF file
EPEric Pasmant
Eric Pasmant
ASAudrey Sabbagh
Audrey Sabbagh
GSGill Spurlock
Gill Spurlock
ILIngrid Laurendeau
Ingrid Laurendeau
EGElisa Grillo
Elisa Grillo
DVDominique Vidaud
Dominique Vidaud
In 5‐10% of patients, neurofibromatosis type 1 (NF1) results from microdeletions that encompass the entire NF1 gene and a variable number of flanking genes. Two recurrent microdeletion types are found in most cases, with microdeletion breakpoints located in paralogous regions flanking NF1 (proximal NF1‐REP‐a and distal NF1‐REP–c for the 1.4 Mb type‐1 microdeletion, and SUZ12 and SUZ12P for the 1.2 Mb type‐2 microdeletion). A more severe phenotype is usually associated with NF1 microdeletion patients than in those with intragenic mutations. We characterized NF1 microdeletions in 70 unrelated NF1 microdeleted patients using a high‐resolution NF1 custom array comparative genomic hybridization (CGH). Genotype‐phenotype correlations were studied in 58 of these microdeletion patients and compared to 389 patients with intragenic truncating NF1 mutations and phenotyped in the same standardized way. Our results confirmed in an unbiased manner the existence of a contiguous gene syndrome with a significantly higher incidence of learning disabilities and facial dysmorphism in microdeleted patients compared to patients with intragenic NF1 mutations. Microdeleted NF1 patients also showed a trend toward significance for childhood overgrowth. High‐resolution array‐CGH identified a new recurrent ∼1.0 Mb microdeletion type, designated as type‐3, with breakpoints in the paralogous regions middle NF1‐REP‐b and distal NF1‐REP–c.

2 August 2013 in Human Mutation
Verified
Journal Article
Closed access
PDF file
ASAudrey Sabbagh
Audrey Sabbagh
EPEric Pasmant
Eric Pasmant
AIApolline Imbard
Apolline Imbard
ALArmelle Luscan
Armelle Luscan
MSMagali Soares
Magali Soares
PWPierre Wolkenstein
Pierre Wolkenstein

25 September 2007 in Gut
Verified
Journal Article
Open access
PDF file
TATarik Asselah
Tarik Asselah
IBIvan Bieche
Ivan Bieche
SNS Narguet
S Narguet
ASA Sabbagh
A Sabbagh
ILI Laurendeau
I Laurendeau
PMP Marcellin
P Marcellin
Background and Aims: The gold standard treatment of chronic hepatitis C (CHC) is combined pegylated interferon and ribavirin. Considering side effects and treatment cost, prediction of treatment response before therapy is important. The aim of this study was to identify a liver gene signature to predict sustained virological response in patients with CHC. Methods: Group A (training set) comprised 40 patients with CHC including 14 non-responders (NRs) and 26 sustained virological responders (SVRs). Group B (validation set) comprised 29 patients including 9 NRs and 20 SVRs. Eleven responder–relapsers were also included. A total of 58 genes associated with liver gene expression dysregulation during CHC were selected from the literature. Real-time quantitative RT-PCR assays were used to analyse the mRNA expression of these 58 selected genes in liver biopsy specimens taken from the patients before treatment. Results: From the Group A data, three genes whose expression was significantly increased in NRs compared with SVRs were identified: IFI-6-16/G1P3, IFI27 and ISG15/G1P2. These three genes also showed significant differences in their expression profiles between NRs and SVRs in the independent sample (Group B). Supervised class prediction analysis identified a two-gene (IFI27 and CXCL9) signature, which accurately predicted treatment response in 79.3% (23/29) of patients from the validation set (Group B), with a predictive accuracy of 100% (9/9) and of 70% (14/20) in NRs and SVRs, respectively. The expression profiles of responder–relapsers did not differ significantly from those of NRs and SVRs, and 73% (8/11) of them were predicted as SVRs with the two-gene classifier. Conclusion: NRs and SVRs have different liver gene expression profiles before treatment. The most notable changes occurred mainly in interferon-stimulated genes. Treatment response could be predicted with a two-gene signature (IFI27 and CXCL9).

6 April 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ASAudrey Sabbagh
Audrey Sabbagh
PDPierre Darlu
Pierre Darlu
BCBrigitte Crouau-Roy
Brigitte Crouau-Roy
EPEstella S. Poloni
Estella S. Poloni
Arylamine N-acetyltransferase 2 (NAT2) is involved in human physiological responses to a variety of xenobiotic compounds, including common therapeutic drugs and exogenous chemicals present in the diet and the environment. Many questions remain about the evolutionary mechanisms that have led to the high prevalence of slow acetylators in the human species. Evidence from recent surveys of NAT2 gene variation suggests that NAT2 slow-causing variants might have become targets of positive selection as a consequence of the shift in modes of subsistence and lifestyle in human populations in the last 10,000 years. We aimed to test more extensively the hypothesis that slow acetylation prevalence in humans is related to the subsistence strategy adopted by the past populations. To this end, published frequency data on the most relevant genetic variants of NAT2 were collected from 128 population samples (14,679 individuals) representing different subsistence modes and dietary habits, allowing a thorough analysis at both a worldwide and continent scale. A significantly higher prevalence of the slow acetylation phenotype was observed in populations practicing farming (45.4%) and herding (48.2%) as compared to populations mostly relying on hunting and gathering (22.4%) (P = 0.0007). This was closely mirrored by the frequency of the slow 590A variant that was found to occur at a three-fold higher frequency in food producers (25%) as compared to hunter-gatherers (8%). These findings are consistent with the hypothesis that the Neolithic transition to subsistence economies based on agricultural and pastoral resources modified the selective regime affecting the NAT2 acetylation pathway. Furthermore, the vast amount of data collected enabled us to provide a comprehensive and up-to-date description of NAT2 worldwide genetic diversity, thus building up a useful resource of frequency data for further studies interested in epidemiological or anthropological research questions involving NAT2.

6 October 2014 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
ECErick Castelli
Erick Castelli
JRJaqueline Ramalho
Jaqueline Ramalho
IPIane O. P. Porto
Iane O. P. Porto
TLThã¡Litta H. A. Lima
Thã¡Litta H. A. Lima
LFLeandro P. Felã­cIo
Leandro P. Felã­cIo
CMCelso Teixeira Mendes-Junior
Celso Teixeira Mendes-Junior
Human Leucocyte Antigen G (HLA-G) belongs to the family of nonclassical HLA class I genes, located within the major histocompatibility complex (MHC). HLA-G has been the target of most recent research regarding the function of class I nonclassical genes. The main features that distinguish HLA-G from classical class I genes are: a) limited protein variability; b) alternative splicing generating several membrane bound and soluble isoforms; c) short cytoplasmic tail; d) modulation of immune response (immune tolerance); e) restricted expression to certain tissues. In the present work, we describe the HLA-G gene structure and address the HLA-G variability and haplotype diversity among several populations around the world, considering each of its major segments (promoter, coding and 3’untranslated regions). For this purpose, we developed a pipeline to reevaluate the 1000Genomes data and recover miscalled or missing genotypes and haplotypes. It became clear that the overall structure of the HLA-G molecule has been maintained during the evolutionary process and that most of the variation sites found in the HLA-G coding region are either coding synonymous or intronic mutations. In addition, only a few frequent and divergent extended haplotypes are found when the promoter, coding and 3’ untranslated regions are evaluated together. The divergence is particularly evident for the regulatory regions. The population comparisons confirmed that most of the HLA-G variability has originated before human dispersion from Africa and that the allele and haplotype frequencies have probably been shaped by strong selective pressures.